San Carlos, CA - Sep 16, 2025 (UTC) - RevOpsis Therapeutics, a biopharmaceutical company pioneering multispecific biologics for vision loss, has received a strategic investment from ExSight Ventures, a venture capital firm dedicated to investing in transformative ophthalmology innovations. While the amount of the investment was not disclosed, the funding will enable RevOpsis to accelerate preclinical development of its lead candidate and expand its pipeline of novel ophthalmic assets.
The investment builds on RevOpsis’s previous $16.5 million seed funding round completed in April 2024, which established the company as a leader in next-generation ophthalmic therapeutics. Founded in 2018 and led by CEO Ram Bhandari, RevOpsis Therapeutics employs its proprietary Surrobody platform to tackle vision loss and target diverse eye conditions with breakthrough therapeutic approaches.
RevOpsis is focused on solving blindness through the rapid discovery and development of novel therapies using its modular Rev-Mod Platform, a revolutionary advancement in multispecific biologics. The company’s therapeutic candidates are specifically designed to achieve improved disease outcomes and extended disease remission by targeting dominant biologic pathways in complex multifactorial diseases affecting vision.
The Rev-Mod Platform uses a modular plug-and-play system to streamline drug discovery and development, representing a new era in multispecific antibody discovery and development. This proprietary technology enables the company to unlock transformative treatments for complex eye diseases, with particular focus on age-related macular degeneration and other vision-threatening conditions.
ExSight Ventures specializes in investing in technologies that preserve and restore vision, making it an ideal strategic partner for RevOpsis as the company advances its innovative ophthalmology pipeline. The partnership aligns with ExSight’s mission to support breakthrough innovations in eye care and vision preservation.
RevOpsis previously participated in the NSF I-Corps Jumpstart program, demonstrating its commitment to translating cutting-edge research into commercial therapeutic solutions. The company has been building its pipeline of IND-enabling studies in age-related macular degeneration while developing additional therapeutic candidates targeting various ophthalmologic conditions.
The current funding will support RevOpsis’s continued advancement toward clinical trials while expanding the company’s research and development capabilities. With multispecific biologics representing a rapidly growing area of therapeutic development, RevOpsis is positioned to capitalize on this emerging opportunity in ophthalmology.
About RevOpsis Therapeutics
RevOpsis Therapeutics is a privately held, next-generation biopharmaceutical company founded in 2018 that is trailblazing a new era in multispecific antibody discovery and development to unlock transformative treatments for complex eye diseases. The company employs its proprietary Surrobody platform and Rev-Mod Platform to tackle vision loss and target diverse eye conditions with potential breakthrough therapeutics. RevOpsis is focused on solving blindness with a vision for the rapid discovery and development of novel therapies using its modular platform technology. The company’s therapeutic candidates are specifically designed to achieve improved disease outcomes and extended disease remission by targeting dominant biologic pathways in complex multifactorial diseases. RevOpsis is led by CEO Ram Bhandari and is headquartered in San Carlos, California.
